aivlosin
eco animal health europe limited - tylwalozyna - Противоинфекционные dla systemowego użycia antybakteryjne preparaty do użytku makrolidy - pheasants; chicken; turkeys; pigs - pigstreatment i methaphylaxis świń энзоотической zapalenie płuc;leczenie świńskiej proliferacyjnej энтеропатии (илеит);leczenie i methaphylaxis biegunki świń. chickenstreatment i methaphylaxis chorób układu oddechowego związanych z галисептикум микоплазмоза u kur. pheasantstreatment chorób układu oddechowego związanych z галисептикум mykoplazmy . turkeystreatment chorób układu oddechowego związanych z tylvalosin wrażliwych szczepów ornithobacterium rhinotracheale w indyków.
tecentriq
roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - Środki przeciwnowotworowe - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq w monoterapii jest przeznaczony do leczenia dorosłych pacjentów z miejscowo-postępowym lub przerzutowym nowotworem po wcześniejszej chemioterapii. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq w monoterapii jest przeznaczony do leczenia dorosłych pacjentów z miejscowo-postępowym lub przerzutowym nowotworem po wcześniejszej chemioterapii. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
fromilid 250 mg/5 ml granulat do sporządzania zawiesiny doustnej
krka, d.d., novo mesto - clarithromycinum - granulat do sporządzania zawiesiny doustnej - 250 mg/5 ml
tylan g 100 premix 100 g/1 kg premiks do sporządzania paszy leczniczej
elanco gmbh - tylozyna (w postaci fosforanu) - premiks do sporządzania paszy leczniczej - 100 g/1 kg - świnia
denagard 450 mg/g granulat do sporządzania roztworu doustnego
elanco gmbh - tiamulini hydrogenofumaras - granulat do sporządzania roztworu doustnego - 450 mg/g - indyk; kura; świnia
denagard 10% 100 mg/g premiks do sporządzania paszy leczniczej
elanco gmbh - tiamulini hydrogenofumaras - premiks do sporządzania paszy leczniczej - 100 mg/g - indyk; królik; kura; świnia
tiamowet 45% granulat 450 mg/g granulat do sporządzania roztworu doustnego
vetoquinol biowet sp. z o.o. - tiamulini hydrogenofumaras - granulat do sporządzania roztworu doustnego - 450 mg/g - indyk; kura; świnia
linco-spectin 100 (222 g + 444,7 g)/1000 g proszek do podania w wodzie do picia
zoetis polska sp. z o.o. - spektynomycyna (w postaci siarczanu) + lincomycini hydrochloridum - proszek do podania w wodzie do picia - (222 g + 444,7 g)/1000 g - kura; świnia
fromilid 125 mg/5 ml granulat do sporządzania zawiesiny doustnej
krka, d.d., novo mesto - clarithromycinum - granulat do sporządzania zawiesiny doustnej - 125 mg/5 ml
vetmulin 450 mg/g granulat do podania w wodzie do picia
huvepharma nv - tiamulini hydrogenofumaras - granulat do podania w wodzie do picia - 450 mg/g - indyk; kura; świnia